international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug

granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change

issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including

(Microsoft Word - MPIC - 4150514765052264 E) -Translation – MPIC 013/2018 August 8, 2018 Subject: Notification of the investment in the distribution company in Cambodia Attn: The President The Stock

the issuer’s core business. In any event, the issuer must not operate business in such a way that involves severely illegal business. For example, human trafficking, drug production or smuggling, or

from 79.01 Million Baht to 74.65 Million Baht or 5.52% due to cancellation of licensor distribution and manufacturing. This affects extensive project cannot apply tender as a results. 2. The Company’s

Company Limited and Phong-Sra Distribution Company Limited (Revise) 30/12/2021 13:23 Notification of the acquisition of assets in ordinary shares of Pongsara-Manufacturing Co., Ltd. and Pongsara

involves severely illegal business. For example, human trafficking, drug smuggling or money laundering etc. Moreover, the issuer must not act in violation or non-compliance with the law, which may cause

% 37.52 55.36 -32.23% Total Revenue 2,101.58 2,164.94 -2.93% 4,298.15 4,270.47 0.65% Cost of hospital operations (1,391.85) (1,483.35) -6.17% (2,906.95) (2,926.87) -0.68% Distribution and Administrative